Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in obesity with heart failure with reduced ejection fraction
IRCT20200209046427N3Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and obesity comparing Tirzepatide with Placebo (2 arms). Primary endpoint: 6-minute walk test distance. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
heart failure with reduced ejection fraction (HFrEF)obesity
Beyond the preview
Go deeper on IRCT20200209046427N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200209046427N3.